Insider Selling: Fennec Pharmaceuticals (TSE:FRX) Director Sells 10,349 Shares of Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 10,349 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of C$10.69, for a total value of C$110,630.81. Following the completion of the sale, the director directly owned 2,709,294 shares in the company, valued at C$28,962,352.86. This represents a 0.38% decrease in their position.

Rostislav Christov Raykov also recently made the following trade(s):

• On Monday, February 2nd, Rostislav Christov Raykov acquired 15,598 shares of Fennec Pharmaceuticals stock. The shares were bought at an average cost of C$3.37 per share, with a total value of C$52,565.26.

Fennec Pharmaceuticals Price Performance

Fennec Pharmaceuticals stock remained flat at C$10.50 during trading on Friday. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83. Fennec Pharmaceuticals Inc. has a 12 month low of C$7.02 and a 12 month high of C$13.83. The company has a market capitalization of C$358.61 million, a P/E ratio of -40.38 and a beta of 2.97. The stock’s 50 day moving average price is C$10.50 and its 200-day moving average price is C$11.41.

Analysts Set New Price Targets

Separately, B.Riley Securit upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Strong Buy”.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.